Article ; Online: Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.
2020 Volume 92, Issue 7, Page(s) 740–746
Abstract: Confronting the challenge of the outbreak of COVID-19 should sharpen our focus on global drug access as a key issue in antiviral therapy testing. The testing and adoption of effective therapies for novel coronaviruses are hampered by the challenge of ... ...
Abstract | Confronting the challenge of the outbreak of COVID-19 should sharpen our focus on global drug access as a key issue in antiviral therapy testing. The testing and adoption of effective therapies for novel coronaviruses are hampered by the challenge of conducting controlled studies during a state of emergency. The access to direct antiviral drugs, such as ribavirin, that have an existing inventory and reliable supply chain may be a priority consideration for therapies developed for the 2019-nCoV infection outbreaks and any strain variants that may emerge. On the basis of the direct antiviral activity of ribavirin against 2019-nCoV in vitro and evidence for potency enhancement strategies developed during the prior SARS and MERS outbreaks, ribavirin may significantly impact our ability to end the lingering outbreaks in China and slow outbreaks in other countries. The apparent COVID-19 pandemic provides an opportunity to follow dosage guidelines for treatment with ribavirin, test new therapeutic concepts, and conduct controlled testing to apply the scientific rigor required to address the controversy around this mainstay of antiviral therapy. |
---|---|
MeSH term(s) | Antiviral Agents/therapeutic use ; Betacoronavirus/drug effects ; Betacoronavirus/genetics ; Betacoronavirus/pathogenicity ; COVID-19 ; Clinical Trials as Topic ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Coronavirus Infections/virology ; Disease Progression ; Drug Administration Schedule ; Gene Expression Regulation, Viral ; Humans ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/virology ; RNA, Viral/antagonists & inhibitors ; RNA, Viral/biosynthesis ; RNA, Viral/genetics ; Ribavirin/therapeutic use ; SARS-CoV-2 ; Signal Transduction |
Chemical Substances | Antiviral Agents ; RNA, Viral ; Ribavirin (49717AWG6K) |
Keywords | covid19 |
Language | English |
Publishing date | 2020-04-10 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 752392-0 |
ISSN | 1096-9071 ; 0146-6615 |
ISSN (online) | 1096-9071 |
ISSN | 0146-6615 |
DOI | 10.1002/jmv.25798 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1320: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.